{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-342334","form_type":"8-K","ticker":"OLMA","cik":"0001750284","company_name":"Olema Pharmaceuticals, Inc.","filed_at":"2026-08-10T20:05:19+00:00","discovered_at":"2026-08-10T20:07:01.470364+00:00","generated_at":"2026-08-10T20:09:52.393671+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Olema Q2 2026 net loss $63.2M, cash $461.1M; OPERA-01 enrollment complete","bullets":["Net loss $63.2M vs $43.8M in Q2 2025; R&D expenses $57.8M vs $43.9M (GAAP).","Cash, equivalents, and marketable securities totaled $461.1M as of June 30, 2026.","Completed enrollment in Phase 3 OPERA-01 (palazestrant monotherapy); top-line data expected Q1 2027.","Announced Bayer collaboration to study OP-3136 plus darolutamide in mCRPC; enrollment starts Q4 2026.","Presented initial Phase 1 data for OP-3136 at ASCO 2026 showing tolerability and anti-tumor activity."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-342334","json":"https://secwatch.observer/filing/0001193125-26-342334.json","markdown":"https://secwatch.observer/filing/0001193125-26-342334.md","text":"https://secwatch.observer/filing/0001193125-26-342334.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1750284/000119312526342334/0001193125-26-342334-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1750284/000119312526342334/olma-20260810.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-10T20:09:52.393671+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}